Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Coupang Inc (CPNG) Price & Performance

Abeona Therapeutics IncTrade
Coupang IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Coupang Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Coupang Inc trades at $16.37 (market cap $29.66B). The key difference: Coupang Inc is far larger — about 70.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.

ABEOCPNG
Market Cap
$421.19M$29.66B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$33.53
52-Week Low
$4.17$15.12
Enterprise Value
$276.10M$29.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Coupang Inc

Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.

Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG